London Health Sciences Centre Announces Firsts In Treatment Option For Blood Circulation
LONDON, Ontario, February 27, 2013 /PRNewswire/ --
London Health Sciences Centre ( LHSC) continues its tradition of innovation as it is the first in North America to use a new blood circulation device and first in the world to use the device in cardiac surgery.
Since December, Dr. Bob Kiaii, cardiac surgeon, and the rest of the cardiac surgery team at LHSC, has been treating patients recovering from heart surgery with the new blood circulation device, named geko™, to help manage swelling resulting from excess fluids following cardiac surgery, a condition known as post-operative edema.
"The device offers patients a drug-free treatment option for a common condition following cardiac surgery and simplifies current strategies to eliminate excess fluids," says Dr. Kiaii. "This is important because excess fluids impede oxygen delivery and wound healing, compromise pulmonary function, and delay resumption of bowel function."The size of a wrist-watch and worn behind the knee, the self-contained geko™ device is designed to increase blood flow by activating the muscle pumps in the lower leg that return blood to the heart, emulating the blood flow rate normally achieved by walking (up to 70 per cent), without the patient having to move or exert energy. Patients can apply the battery powered device themselves and have the control to turn it off or on. "Dr. Kiaii and his team continue to build upon London Health Sciences Centre's legacy of innovation," says Bonnie Adamson, President and CEO, LHSC. "This is another example of LHSC utilizing advanced technologies to improve outcomes for the patients we serve." Dennis Findlay of London, Ontario was the first patient offered the new treatment by Dr. Kiaii immediately after his triple-bypass surgery in December. "I wore it every day while I was in hospital. It was painless and barely noticeable and I'm grateful it helped my recovery," describes Findlay. Approximately 60 patients have benefited from the device as part of their treatment plan. "Early observational use of the geko™ device has shown promise and we are planning to conduct a controlled trial to further investigate its health benefits," continues Dr. Kiaii.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts